Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)

This study has been completed.
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01169649
First received: July 21, 2010
Last updated: February 12, 2014
Last verified: February 2014
  Purpose

The purpose of this study is to test a new drug called MK-2206. This study is a phase II study. In cancer studies, a phase II study is to find out what effects, good and/or bad, a new treatment has against a certain type of cancer.

MK-2206 is an oral medication known as a targeted therapy. By attaching to the target, we hope that MK-2206 may stop the cancer cells from further growth and dividing. This study will help find out if MK-2206 is a helpful drug when taken in patients with neuroendocrine tumor.


Condition Intervention Phase
PANCREAS
Neuroendocrine
Drug: MK-2206
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Clinical and Translational Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)

Resource links provided by NLM:


Further study details as provided by Memorial Sloan-Kettering Cancer Center:

Primary Outcome Measures:
  • To assess overall response. [ Time Frame: every 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the safety. [ Time Frame: Will be assessed every other week, on treatment weeks only. ] [ Designated as safety issue: Yes ]
    Safety will be evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.0, based on recorded adverse events, physical examinations, and clinical laboratory assessments.

  • To evaluate tolerability. [ Time Frame: Will be assessed every other week, on treatment weeks only. ] [ Designated as safety issue: No ]
  • To evaluate adverse event profiles. [ Time Frame: Will be assessed every other week, on treatment weeks only. ] [ Designated as safety issue: Yes ]
  • To evaluate tumors for expression for putative markers along the PI3K pathway. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Archival tissue will be tested for genotype and mutational status of PI3K, and BRAF in stages 1 and 2.

  • To assess overall survival. [ Time Frame: every three months until death, or the cut-off date for the last protocol mandated analysis, whichever occurs first. ] [ Designated as safety issue: No ]

Enrollment: 8
Study Start Date: July 2010
Study Completion Date: February 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: islet cell carcinomas
This is an open label phase II study of MK-2206 administered to patients with metastatic neuroendocrine tumors.
Drug: MK-2206
MK-2206 will be given orally 200 mg qw as given in the prior Ph1 clinical trial that demonstrated safety, tolerability and adequate PK/PD values at this dose. Follow-up imaging scans will be performed every 12 weeks to evaluate response. Patients must take MK-2206 orally at least 2 hours before or 2 hours after food or a meal.
Experimental: carcinoid tumors
This is an open label phase II study of MK-2206 administered to patients with metastatic neuroendocrine tumors.
Drug: MK-2206
MK-2206 will be given orally 200 mg qw as given in the prior Ph1 clinical trial that demonstrated safety, tolerability and adequate PK/PD values at this dose. Follow-up imaging scans will be performed every 12 weeks to evaluate response. Patients must take MK-2206 orally at least 2 hours before or 2 hours after food or a meal.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with histologically or cytologically confirmed moderately to well differentiated metastatic or unresectable carcinoid or islet cell tumors.
  • Patient has at least one measurable lesion greater than or equal to 20 mm on CT or MRI imaging.
  • Patients who are on therapy with a somatostatin analog are eligible for entry but must be on a stable dose for at least 3 months with no evidence of tumor shrinkage during that time period.
  • Patient ≥18 years of age on the day of signing informed consent.
  • Patient has performance status 0-1 on the ECOG Performance Scale.
  • Patient has adequate organ function as indicated by the following laboratory values:
  • Absolute Neutrophil Count (ANC)≥1,500/mcL
  • Platelets ≥100,000/mcL
  • Hemoglobin ≥9 g/dL
  • Serum Creatinine ≤2 times the upper limit of normal (ULN)/ OR calculated CrCl ≥60 mL/min (patients with creatinine levels ≥2 times the ULN only). Patient may not be on dialysis
  • Serum total bilirubin ≤1.5 times the ULN
  • AST (SGOT) and ALT (SGPT) ≤5 times the ULN
  • HgbA1c ≤ 8%
  • Fasting Glucose ≤120 mg/dl
  • Creatinine clearance should be calculated by the Cockcroft-Gault method.Fasting is defined as at least 4 hours without oral intake.
  • Patient has voluntarily agreed to participate by giving written informed consent.
  • Previous local therapy (e.g. chemoembolization or bland embolization) is allowed if completed > 6 weeks or 5X half-life prior to study entry. For patients who received local therapy prior to study entry, there must be either documented growth of measurable disease within the embolization field or outside of the embolization field, or both, prior to study entry if the area of the embolization field was the only site of measurable disease.
  • Previous chemotherapy, radiotherapy, and/or biologic therapy, including investigational agents, is/are allowed if completed > 4 weeks prior to study entry (>6 weeks if last regimen contained bevacizumab, BCNU or mitomycin C, and > 6 weeks from last dose of radiation therapy or radiopharmaceutical.
  • Patients must not have disease that is currently amenable to curative surgery. Prior surgery is allowed no less than 6 weeks prior to study entry.
  • Patients with diabetes mellitus are eligible for study entry but must have controlled diabetes as defined by hemoglobin A1c <8.0% within 2 weeks of initiation of protocol therapy.

Exclusion Criteria:

  • Patient has toxicities from prior therapies that have not resolved to grade 1 or grade 0.
  • Patient has known active CNS metastases and/or carcinomatous meningitis are excluded. However, patients with CNS metastases who have completed a course of therapy would be eligible for the study provided they are clinically stable for 1 month prior to entry as defined as: (1) no evidence of new or enlarging CNS metastasis (2) off steroids that are used to minimize surrounding brain edema.
  • Patient has an active malignancy of metastatic potential other than the known carcinoid or islet cell tumor, for the past 3 years.
  • Patient has a known hypersensitivity to the components of study drug (MK-2206) or its analogs that is not treatable by premedication with antihistamines and steroids.
  • Patient has a condition, including but not limited to
  • symptomatic congestive heart failure
  • unstable angina pectoris
  • serious cardiac arrhythmia
  • history or current evidence of a myocardial infarction during the last 6 months, and/or a current ECG tracing that is abnormal in the opinion of the treating investigator
  • QTc prolongation >450 msec (Bazett's formula)
  • Patient with evidence of clinically significant bradycardia (HR <50), or a history of clinically significant bradyarrhythmias such as sick sinus syndrome, 2nd degree AV block (Mobitz Type 2).
  • Patient with uncontrolled hypertension (i.e., 160/90 mHg SiBP). Patients who are controlled on antihypertensive medication will be allowed to enter the study.
  • Patient at significant risk for hypokalemia (e.g., patients on high dose diuretics, or with recurrent diarrhea)
  • Patient is a known diabetic who is poorly controlled (HBAc>8%)
  • Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.
  • Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Patient is, at the time of signing informed consent, a regular user (including ―recreational use‖) of any illicit drugs or had a recent history (within the last year) of drug or alcohol abuse.
  • Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study.
  • Patient is known to be Human Immunodeficiency Virus (HIV)-positive
  • Patient has known history of Hepatitis C or active Hepatitis A or B.
  • Patient has symptomatic ascites or pleural effusion. A patient who is clinically stable following treatment for these conditions is eligible.
  • Patient has prior treatment with an mTOR inhibitor such as afinitor, sirolimus, or temsirolimus.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01169649

Locations
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Merck Sharp & Dohme Corp.
Investigators
Principal Investigator: Diane Reidy-Lagunes, MD,MS Memorial Sloan-Kettering Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT01169649     History of Changes
Other Study ID Numbers: 10-067
Study First Received: July 21, 2010
Last Updated: February 12, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Memorial Sloan-Kettering Cancer Center:
MK-2206
Neuroendocrine Tumors
10-067

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue

ClinicalTrials.gov processed this record on April 14, 2014